A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

Clinical trial NCT06306339 · UNKNOWN

Trial details

NCT number: NCT06306339
Sponsor: ImmuneMed, Inc.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Moderate to Severe Rheumatoid Arthritis

Start date: 2024-03-01
Primary completion: 2025-05-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.